Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2/3 1

Status

Withdrawn 3Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Other 1

Conditions

Pancreatic Neoplasms 2Opioid-Induced Constipation 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × methylnaltrexone × Clear all
NCT04083651 2021-05-07

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Bausch Health Americas, Inc.

Phase 2/3 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT04151719 2021-05-07

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Bausch Health Americas, Inc.

Phase 3 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT00858754 2019-11-29

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Bausch Health Americas, Inc.

Phase 4 Withdrawn
Other

Opioid-Induced Constipation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡